Rebuilding the spine Acorda Therapeutics, Inc. by Wells, William A
Innovations
Rebuilding the spine
Acorda Therapeutics, Inc.
Chemistry & Biology 2000, 7:24–25
1074-5521/00/$ – see front matter © 2000
Elsevier Science Ltd. All rights reserved.
Hype does not come naturally to
Andrew Blight. As Vice President for
Research and Development at Acorda
Therapeutics, Inc. (Hawthorne, New
York), Blight trusts that the media will
always portray his company’s goal — a
cure for spinal cord injury (SCI) — as
being closer than it really is. But while
Blight is struggling with the realities of
complex drug trials, the basic science
of central nervous system (CNS)
regeneration looks downright exciting.
A new generation of neuroscientists,
trained in the young field of nerve
growth and guidance, is hungry to
apply their knowledge to CNS
regeneration, even as the pioneers in
the field are getting molecular.
“The regeneration field is
exploding right now,” says Ben Barres
of Stanford University, California. Still,
Acorda CEO Ron Cohen realizes the
immensity of the challenge.
“Someone has taken a hatchet to the
major power grid cable coming into
New York City,” says Cohen. “An
engineering tour de force is required.”
The first signs of hope
Cohen’s realism comes from his
medical training — he even avoided
a neurology residency because, he
says, “the definition of neurology
practice was diagnose and adios.”
After six years in another biotech
company, however, he “felt that SCI
chose me,” he says. “I became
convinced that this was the right
time to work on nerve repair — that
it was not a quixotic venture.”
The first glimmer of hope for
CNS regeneration came in 1981,
when Samuel David and Albert
Aguayo of McGill University in
Montreal showed that lesioned CNS
neurons could regrow if they were
provided with a bridge made of tissue
from the peripheral nervous system
(PNS). “I had been taught that when
you damage a nerve in the CNS it
cannot recover,” says Cohen. “That
had not changed as dogma since the
days when medical information came
on papyrus.” The 1981 experiments
“told us for the first time that
neurons in the CNS have the
capacity to grow,” says David.
The growth of a few nerve cell
axons was exciting, but not enough
to justify a company. “There are 2
million axons in an average spinal
cord,” says Cohen. “We had no idea
how to grow back and reconnect 1.5
or 2 million axons, so no one even
bothered. It was so daunting.”
Will Superman walk again? First
the exciting science must confront
formidable practical challenges. 
Blight’s results told Cohen he
didn’t have to reconnect all the
axons. When Blight took a careful
look at damaged spinal cords, he
found that animals that retained less
than 10% of their axons intact could
still walk. Meanwhile, Wise Young at
New York University Medical
Center had coordinated a study
showing that high doses of
methylprednisolone, a corticosteroid
thought to act as an anti-oxidant, had
beneficial effects if given within 8
hours of injury. The effect was
modest, but it proved that SCI was a
tractable problem. Young helped
Cohen form Acorda in 1995.
A small molecule fix for SCI
Blight’s inspection of damaged spinal
cords had also uncovered a great
number of nerves that were uncut,
but lacking their insulating sheath of
myelin. This provided the rationale
for tests of 4-aminopyridine (4-AP or
fampridine), an existing experimental
drug that was known to block
potassium channels exposed by the
missing myelin sheath. Although
4-AP will not heal SCI, and cannot
substitute for all the functions of
myelin, a continuous dose may
improve symptoms.
A slow-release formulation of 4-AP
has been supplied by Elan
Corporation, plc (Dublin, Ireland) and
tested by Acorda in two phase II
trials, with a third to follow in 2000.
Cohen says multiple trials have been
necessary in part because of the
difficulty of defining accurate
measures of effectiveness. “The
beneficial effects depend on what
axon groups have been demyelinated,
but the FDA forces you to select a
primary outcome,” says Cohen.
Acorda has come up with its own
scoring system to evaluate
improvements in areas such as bowel,
urinary and sexual function, and
hopes to enter phase III trials in 2000. 
The difficulty with trials confirms
that 4-AP is not a wonder cure, but
“no one’s ever felt that,” says Blight.
“It’s a first step to do something in
the chronic stage.” Cohen says the
company is “disproportionately
reliant on the success of our lead
product,” but he is confident that
4-AP will be the company’s first
major source of cash.
Grand ambition
The benefits promised by 4-AP may
improve life for those with SCI, but
Christopher Reeve’s campaign to cure
SCI is promising more than improved
urinary function. “Motor function is
the keys under the lamppost — this is
where people want to find
improvement,” says Blight. “If you
find other improvements it’s not such
an obvious sell.”
The research community has
obliged with a string of ‘cures’ in
animal studies, some of which have
yielded little in the way of practical
promise for humans. “There is a
whole series of what look like flashes
in the pan,” says Blight. “This is a
phenomenon that is more
predominant in spinal cord repair
than in any other field. That doesn’t
help the reputation of the field.”
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“You can’t blame people for the
waves of excitement, as these are
important advances,” says Marc
Tessier-Lavigne (University of
California, San Francisco). “On the
other hand, what really amounted to
proof-of-principle experiments should
have been couched in those terms.”
The philosophy at Acorda is to
lower both expectations and the
threshold for declaring success. “The
aim is to chip away at the problem,”
says Blight. “Most responsible
people in the field think the idea of a
magic bullet is romantic. It’s a matter
of moving forward by inches rather
than taking one great leap.”
“From the get-go we understood it
would be a multipart problem,” says
Cohen. “We can give people usable
single functions with monotherapy.
But if you are talking about getting
people out of wheelchairs, that will
take multiple approaches.”
Overcoming the barriers
Regeneration requires overcoming the
CNS’s resistance to growth. “There
are probably many barriers,” says
Blight. “The primary barrier to
regeneration is probably understanding
what the primary barrier is.”
An obvious physical barrier is scar
tissue, which Proneuron
Biotechnologies, Inc. (Ness-Ziona,
Israel) hopes to combat with
autotransplanted macrophages, in
human trials in 2000. Acorda,
meanwhile, is looking at growth
signals: both the lack of positive signals
and the presence of inhibitory signals. 
Their positive signal is L1, a cell
adhesion molecule found in the
developing but not mature CNS.
Cohen says L1 could be used for
acute or chronic injuries, with the
mechanics of L1 delivery to be
determined. One option is to attach
L1 to the artificial fibers designed by
Acorda collaborator Patrick Tresco
(University of Utah, Salt Lake City),
in the hope that the fibers will act
like pioneering axons that instruct
other axons to follow them. Delivery
may be restricted to a small area
around the site of injury. 
Acorda’s anti-inhibitory program is
focused on the M1 IgM antibodies
discovered by Moses Rodriguez
(Mayo Clinic, Rochester, Minnesota).
Rodriguez stumbled on M1 after
immunizing mice with myelin to
increase the symptoms of
experimental multiple sclerosis (MS),
an autoimmune demyelinating
disease. But instead his immunization
yielded protective M1 auto-antibodies.
M1 antibodies bind to
oligodendrocytes — the myelinating
cells — and probably act both by
turning on oligodendrocytes, and by
recruiting scavenger immune cells to
dispose of damaged oligodendrocytes.
If animal studies are successful,
Acorda will test M1 initially in MS.
The M1 antibodies may be
related to the IN-1 IgM antibody,
which Martin Schwab (University of
Zurich, Switzerland) used in 1990 to
achieve dramatic recoveries from SCI
in rats. IN-1 recognizes at least one of
several myelin-associated nerve
growth inhibitors (papers announcing
the cloning of the major IN-1 target
are in press), but has not been further
developed by its licensee, Regeneron
Pharmaceuticals (Tarrytown, New
York). Regeneron has switched its
emphasis to cancer and the immune
system, but has not released the IN-1
technology back to Schwab. “It
drives me crazy, and it drives patients
even more crazy to think that time
passes by,” says Schwab. 
Schwab has not, however,
managed to replace the pentameric
IgM antibody with a simpler IgG, and
recent evidence from McGill’s David
suggests that IN-1 may not be the
whole story. In the December 1999
issue of Neuron, David reports that rats
immunized with a myelin preparation
show a greater regenerative response
than is seen with IN-1 alone. Myelin
injections into humans are impractical
because of fears of MS, but David’s
experiment suggests that effective
therapy will follow once the important
inhibitors are molecularly defined.
The preoccupation thus far has
been on neuron growth not wiring.
Past experiments have shown
“remarkable specificity,” says
Tessier-Lavigne. “That suggests
there is information that can guide
the axons.” Cohen agrees that
“there’s a certain amount of black
box thinking that as long as you get
the axons across they’ll figure out a
way to connect properly. And even if
they don’t the brain will be plastic
enough to translate it.”
Rebuilding the spine
“Every year there is a theme at the
Society for Neuroscience meeting,”
says Cohen. “This year was the year
of the stem cell.” 
Stem cells are perhaps our best
chance at reconstructing a damaged
spinal cord. Human safety trials have
been done with fetal cell transplants,
but few of those cells turn into
neurons. Acorda’s proposed solution
involves their patented stem cells
that produce only neurons.
To promote growth and
re-myelination, others have
transplanted Schwann cells (the PNS
equivalent of oligodendrocytes).
Unfortunately, Schwann cells and
oligodendrocytes erect an inhibitory
barrier when they encounter each
other. Olfactory ensheathing cells
may be the answer, as these cells
guide regenerating olfactory neurons
from the PNS into the brain. Early
transplants look promising, although
the migration of the transplanted
cells encourages some researchers
and alarms others.
Cohen describes himself as the
company’s “biggest skeptic” about
cell therapy. “It’s very difficult to
produce a reproducible therapy out of
cells,” he says. “I’m wary of it.” But
in the end it may be the only true
answer. “If we were talking about
improving on balloon angioplasty
then don’t bother,” he says. “But here
we have a true tissue engineering
problem. It stands to reason that if we
hope to solve this we have to bite the
bullet and deal with cells.”
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